Point mutation of estrogen receptor (ER) in the ligand-binding domain changes the pharmacology of antiestrogens in ER-negative breast cancer cells stably expressing complementary DNAs for ER. (Q41590531)
Jump to navigation
Jump to search
scientific article published on December 1992
Language | Label | Description | Also known as |
---|---|---|---|
English | Point mutation of estrogen receptor (ER) in the ligand-binding domain changes the pharmacology of antiestrogens in ER-negative breast cancer cells stably expressing complementary DNAs for ER. |
scientific article published on December 1992 |
Statements
1 reference
Point mutation of estrogen receptor (ER) in the ligand-binding domain changes the pharmacology of antiestrogens in ER-negative breast cancer cells stably expressing complementary DNAs for ER. (English)
1 reference
V C Jordan
1 reference
S Y Jiang
1 reference
S M Langan-Fahey
1 reference
A L Stella
1 reference
R McCague
1 reference
1 December 1992
1 reference
1 reference
6
1 reference
12
1 reference
2167-2174
1 reference
Identifiers
1 reference
1 reference